Yumanity Therapeutics Shares Drop 29% After Results for Parkinson's Treatment Trial

By Chris Wack

Yumanity Therapeutics Inc. shares fell 29% to $6.05 after the company reported that its lead product candidate, YTX-7739 achieved its primary endpoints in a Phase 1b clinical trial in patients with mild-to-moderate Parkinson's disease.

Yumanity said YTX-7739 was generally well tolerated, and results were consistent with earlier studies in healthy volunteers and preclinical models. YTX-7739 was shown to inhibit its primary target, stearoyl-CoA desaturase, an enzyme whose inhibition has been closely linked to neuronal survival and improved motor function in a Parkinson's disease model, the company said.

The company said that after 28 days of dosing there were no statistically significant differences in clinical assessments or most exploratory biomarkers. Quantitative electroencephalogram assessments of the effect of YTX-7739 on brain activity were completed in a subset of eight patients and demonstrated a statistically significant change compared to baseline, suggestive of a potential improvement in synaptic function.

The company said it expects to further validate the role of the diagnostic marker in future clinical studies.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

November 10, 2021 10:30 ET (15:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.